Predicting the Response of Patients Treated with Lu-DOTATATE Using Single-photon Emission Computed Tomography-Computed Tomography Image-based Radiomics and Clinical Features

Overview

Journal J Med Signals Sens

Specialty Biomedical Engineering

Date 2024 Nov 27

PMID 39600984

Authors

Baharak Behmanesh

Akbar Abdi-Saray

Mohammad Reza Deevband

Mahasti Amoui

Hamid R Haghighatkhah

Ahmad Shalbaf

Affiliations

Soon will be listed here.

Abstract

Background: In this study, we want to evaluate the response to Lutetium-177 (Lu)-DOTATATE treatment in patients with neuroendocrine tumors (NETs) using single-photon emission computed tomography (SPECT) and computed tomography (CT), based on image-based radiomics and clinical features.

Methods: The total volume of tumor areas was segmented into 61 SPECT and 41 SPECT-CT images from 22 patients with NETs. A total of 871 radiomics and clinical features were extracted from the SPECT and SPECT-CT images. Subsequently, a feature reduction method called maximum relevance minimum redundancy (mRMR) was used to select the best combination of features. These selected features were modeled using a decision tree (DT), random forest (RF), K-nearest neighbor (KNN), and support vector machine (SVM) classifiers to predict the treatment response in patients. For the SPECT and SPECT-CT images, ten and eight features, respectively, were selected using the mRMR algorithm.

Results: The results revealed that the RF classifier with feature selection algorithms through mRMR had the highest classification accuracies of 64% and 83% for the SPECT and SPECT-CT images, respectively. The accuracy of the classifications of DT, KNN, and SVM for SPECT-CT images is 79%, 74%, and 67%, respectively. The poor accuracy obtained from different classifications in SPECT images (≈64%) showed that these images are not suitable for predicting treatment response.

Conclusions: Modeling the selected features of SPECT-CT images based on their anatomy and the presence of extensive gray levels makes it possible to predict responses to the treatment of Lu-DOTATATE for patients with NETs.

References

Laudicella R, Comelli A, Liberini V, Vento A, Stefano A, Spataro A . [Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [Lu]DOTATOC PRRT: The "Theragnomics" Concept. Cancers (Basel). 2022; 14(4). PMC: 8870649. DOI: 10.3390/cancers14040984. View

Prabha A, Yadav J, Rani A, Singh V . Design of intelligent diabetes mellitus detection system using hybrid feature selection based XGBoost classifier. Comput Biol Med. 2021; 136:104664. DOI: 10.1016/j.compbiomed.2021.104664. View

Kolossvary M, Kellermayer M, Merkely B, Maurovich-Horvat P . Cardiac Computed Tomography Radiomics: A Comprehensive Review on Radiomic Techniques. J Thorac Imaging. 2017; 33(1):26-34. DOI: 10.1097/RTI.0000000000000268. View

Camus B, Cottereau A, Palmieri L, Dermine S, Tenenbaum F, Brezault C . Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review. J Clin Med. 2021; 10(6). PMC: 8003169. DOI: 10.3390/jcm10061267. View

Nicolini S, Bodei L, Bongiovanni A, Sansovini M, Grassi I, Ibrahim T . Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2021; 48(10):3260-3267. PMC: 9346628. DOI: 10.1007/s00259-021-05236-z. View

Liberini V, Rampado O, Gallio E, De Santi B, Ceci F, Dionisi B . Ga-DOTATOC PET/CT-Based Radiomic Analysis and PRRT Outcome: A Preliminary Evaluation Based on an Exploratory Radiomic Analysis on Two Patients. Front Med (Lausanne). 2021; 7:601853. PMC: 7870479. DOI: 10.3389/fmed.2020.601853. View

Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T . ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012; 95(2):157-76. DOI: 10.1159/000335597. View

Tang J, Yang B, Adams M, Shenkov N, Klyuzhin I, Fotouhi S . Artificial Neural Network-Based Prediction of Outcome in Parkinson's Disease Patients Using DaTscan SPECT Imaging Features. Mol Imaging Biol. 2019; 21(6):1165-1173. DOI: 10.1007/s11307-019-01334-5. View

Kunikowska J, Zemczak A, Kolodziej M, Gut P, Lon I, Pawlak D . Tandem peptide receptor radionuclide therapy using Y/Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience. Eur J Nucl Med Mol Imaging. 2020; 47(4):922-933. PMC: 7075861. DOI: 10.1007/s00259-020-04690-5. View

10.

Cai Y, Huang T, Hu L, Shi X, Xie L, Li Y . Prediction of lysine ubiquitination with mRMR feature selection and analysis. Amino Acids. 2011; 42(4):1387-95. DOI: 10.1007/s00726-011-0835-0. View

11.

Xu J, Yang J, Feng Y, Zhang J, Zhang Y, Chang S . MRI Feature-Based Nomogram Model for Discrimination Between Non-Hypervascular Pancreatic Neuroendocrine Tumors and Pancreatic Ductal Adenocarcinomas. Front Oncol. 2022; 12:856306. PMC: 9160740. DOI: 10.3389/fonc.2022.856306. View

12.

Spada F, Campana D, Lamberti G, Laudicella R, Dellamano R, Dellamano L . [Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective. Eur J Nucl Med Mol Imaging. 2021; 49(6):2037-2048. PMC: 9016001. DOI: 10.1007/s00259-021-05656-x. View

13.

Coroller T, Grossmann P, Hou Y, Velazquez E, Leijenaar R, Hermann G . CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. Radiother Oncol. 2015; 114(3):345-50. PMC: 4400248. DOI: 10.1016/j.radonc.2015.02.015. View

14.

Ding C, Han H, Li Q, Yang X, Liu T . iT3SE-PX: Identification of Bacterial Type III Secreted Effectors Using PSSM Profiles and XGBoost Feature Selection. Comput Math Methods Med. 2021; 2021:6690299. PMC: 7806399. DOI: 10.1155/2021/6690299. View

15.

Sala E, Mema E, Himoto Y, Veeraraghavan H, Brenton J, Snyder A . Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging. Clin Radiol. 2016; 72(1):3-10. PMC: 5503113. DOI: 10.1016/j.crad.2016.09.013. View

16.

Horvat N, Bates D, Petkovska I . Novel imaging techniques of rectal cancer: what do radiomics and radiogenomics have to offer? A literature review. Abdom Radiol (NY). 2019; 44(11):3764-3774. PMC: 6824982. DOI: 10.1007/s00261-019-02042-y. View

17.

Dhanani J, Pattison D, Burge M, Williams J, Riedel B, Hicks R . Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report. J Crit Care. 2020; 60:319-322. DOI: 10.1016/j.jcrc.2020.08.011. View

18.

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

19.

Ahn H, Lee H, Kim S, Hyun S . Pre-treatment F-FDG PET-based radiomics predict survival in resected non-small cell lung cancer. Clin Radiol. 2019; 74(6):467-473. DOI: 10.1016/j.crad.2019.02.008. View

20.

Behmanesh B, Abdi-Saray A, Deevband M, Amoui M, Haghighatkhah H . Radiomics Analysis for Clinical Decision Support in 177Lu-DOTATATE Therapy of Metastatic Neuroendocrine Tumors using CT Images. J Biomed Phys Eng. 2024; 14(5):423-434. PMC: 11462270. DOI: 10.31661/jbpe.v0i0.2112-1444. View